Nature, Data, And Power: How Hegemonies Shaped This Special Section

Systems of oppression—racism, colonialism, misogyny, cissexism, ableism, heteronormativity, and more—have long shaped the content and practice of science. But opportunities to reckon with these influences are rarely found within academic science, even though such critiques are well developed in the social sciences and humanities. In this special section, we attempt to bring cross-disciplinary conversations among ecology, evolution, behavior, and genetics on the one hand and critical perspectives from the social sciences and humanities on the other into the pages—and in front of the readers—of a scientific journal. In this introduction to the special section, we recount and reflect on the process of running this cross-disciplinary experiment to confront harms done in the name of science and envision alternatives

Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions

Pancreatic cancer (PDAC) is an aggressive and chemoresistant disease, representing the fourth cause of cancer related deaths in western countries. Majority of patients have unresectable, locally advanced or metastatic disease at time of diagnosis and the 5-year survival rate in these conditions is extremely low. For more than a decade gemcitabine has been the cornerstone of metastatic PDAC treatment, although survival benefit was very poor. PDAC cells are surrounded by an intense desmoplastic reaction that may create a barrier to the drugs penetration within the tumor. Recently PDAC stroma has been addressed as a potential therapeutic target. Nano albumin bound (Nab)-paclitaxel is an innovative molecule depleting tumor stroma, through interaction between albumin and secreted protein acidic and rich in cysteine. Addition of nab-paclitaxel to gemcitabine has showed activity and efficacy in metastatic PDAC first-line treatment improving survival and overall response rate vs gemcitabine alone in the MPACT phase III study. This combination represents one of the standards of care in advanced PDAC therapy and is suitable to a broader spectrum of patients compared to other schedules. Nab-paclitaxel is under investigation as a backbone of chemotherapy in novel combinations with target agents or immunotherapy in locally advanced or metastatic PDAC. In this article, we provide an updated and critical overview about the role of nab-paclitaxel in PDAC treatment based on the latest advances in preclinical and clinical research. Furthermore, we focus on the use of nab-paclitaxel within the context of metastatic PDAC treatment landscape and we discuss about future implications in the light of current clinical ongoing trials

Empowering innovative improvements through creative construction procurement

The heightened state of flux in the construction industry in general and construction procurement strategies in particular, provides welcome opportunities to inject innovative improvements. While some improvements are generated from within the construction industry itself, these evolve sluggishly along prolonged learning curves. These are compared with lessons to be learnt and examples to be drawn from manufacturing in the development of a marketable product. A product development focus is thus advocated in re-integrating segregated groups and in empowering and inspiring the innovations that are needed to achieve the dramatic productivity gains now demanded from the construction industry. © 2001, MCB UP Limite